Table 2.
Cumulative incidence of extraarticular rheumatoid arthritis at 10-year follow up
| Period of RA Incidence | |||||
|---|---|---|---|---|---|
|
| |||||
| 1985-1999 (n = 296) | 2000-2014 (n = 611) | ||||
|
| |||||
| Extraarticular Manifestations* | Number of Events | 10-year Cumulative Incidence %, (95% CI) | Number of Events | 10-year Cumulative Incidence %, (95% CI) | HR for time period (95% CI)** |
| Any ExRA | 138 | 45.1 (39.4, 51.6) | 201 | 31.6 (27.3, 36.5) | 0.65 (0.51, 0.82) |
| Severe ExRA | 23 | 7.1 (4.7, 10.9) | 33 | 6 (3.8, 9.3) | 0.72 (0.40, 1.29) |
| Pericarditis | 5 | 2 (0.8, 4.7) | 10 | 2.2 (1.0, 4.6) | 1.09 (0.36, 3.29) |
| Pleuritis | 7 | 2.1 (1.0, 4.8) | 7 | 0.7 (0.03, 1.9) | 0.51 (0.15, 1.68) |
| Felty’s syndrome | 2 | 0.7 (0.2, 2.7) | 0 | 0 | -- |
| Vasculitis¥ | 5 | 1.8 (0.7, 4.2) | 2 | 0.4 (0.1, 1.8) | -- |
| Neuropathy | 5 | 1.4 (0.5, 3.6) | 8 | 0.8 (0.3, 2.4) | 0.65 (0.19, 2.28) |
| Scleritis | 0 | 0 | 3 | 1.4 (0.5, 4.5) | -- |
| Episcleritis | 2 | 0.3 (0.05, 2.4) | 6 | 0.6 (0.1, 2.4) | -- |
| Other ExRA | 119 | 41.4 (35.9, 47.9) | 151 | 28.8 (24.8, 33.5) | 0.67 (0.53, 0.86) |
| Keratoconjunctivitis sicca | 49 | 15.8 (11.9, 20.9) | 86 | 14.8 (11.5, 19.1) | 0.90 (0.62, 1.31) |
| Xerostomia | 1 | 0.3 (0.05, 2.4) | 19 | 3.6 (2.1, 6.3) | -- |
| Sjogren’s syndrome | 32 | 10.1 (7.1, 14.3) | 47 | 8.2 (5.7, 11.7) | 0.70 (0.44, 1.13) |
| Pulmonary fibrosis | 15 | 5.2 (3.1, 8.7) | 20 | 2.8 (1.7, 4.8) | 0.62 (0.30, 1.31) |
| Bronchiolitis obliterans | 2 | 0.7 (0.2, 3.0) | 1 | 0.2 (0.02, 1.2) | -- |
| Organizing pneumonia | 2 | 0.3 (0.05, 2.4) | 2 | 0.3 (0.09, 1.4) | -- |
| Cervical myelopathy | 4 | 1.4 (0.5, 3.8) | 1 | 0.2 (0.03, 1.6) | -- |
| Subcutaneous nodules | 90 | 30.9 (25.8, 37.1) | 94 | 15.8 (12.9, 19.4) | 0.52 (0.39, 0.70) |
| Other nodules | 0 | 0 | 9 | 1.2 (0.5, 3.0) | -- |
Abbreviations: ExRA = extraarticular manifestation of rheumatoid arthritis, HR = hazard ratio; RA = rheumatoid arthritis, CI = confidence interval.
HR reaching statistical significance in bold.
*
There were no cases of retinal vasculitis, glomerulonephritis, or amyloidosis in either cohort;
**
Adjusted for age and sex. Must have at least 5 events in each group;
¥
Included major cutaneous and internal organ vasculitis